Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Deferred Taxes: 2020-2025

Historic Deferred Taxes for Catalyst Pharmaceuticals (CPRX) over the last 5 years, with Sep 2025 value amounting to -$2.4 million.

  • Catalyst Pharmaceuticals' Deferred Taxes fell 128.16% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$217,000, marking a year-over-year decrease of 101.96%. This contributed to the annual value of $9.4 million for FY2024, which is 47.31% down from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Deferred Taxes stood at -$2.4 million for Q3 2025, which was down 199.30% from $2.4 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Deferred Taxes high stood at $13.9 million for Q3 2023, and its period low was -$2.7 million during Q4 2021.
  • In the last 3 years, Catalyst Pharmaceuticals' Deferred Taxes had a median value of $1.7 million in 2024 and averaged $2.7 million.
  • Its Deferred Taxes has fluctuated over the past 5 years, first tumbled by 269.03% in 2021, then skyrocketed by 1,592.83% in 2023.
  • Catalyst Pharmaceuticals' Deferred Taxes (Quarterly) stood at -$2.7 million in 2021, then soared by 53.19% to -$1.3 million in 2022, then surged by 31.28% to -$883,000 in 2023, then crashed by 189.35% to -$2.6 million in 2024, then tumbled by 128.16% to -$2.4 million in 2025.
  • Its last three reported values are -$2.4 million in Q3 2025, $2.4 million for Q2 2025, and $2.3 million during Q1 2025.